Sarah Ann Goodchild,Lyn Margaret OBrien,Robert John Phillpotts,Stuart David Perkins
申请号：
US13497716
公开号：
US20120244150A1
申请日:
2010.09.20
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present disclosure relates to an anti-VEEV humanised antibody or a fragment thereof comprising a framework 1, 2, 3, 4, S or 6 CDR regions independently selected from SEQ ID Nos: 2, 3, 4, 5, 6 or 7 characterised in that the antibody or fragment comprises in the framework at least one amino acid, that positively influences the binding/activity of the antibody, from the original murine antibody 1A3B7, pharmaceutical composition comprising same, methods of preparing the antibody or fragment and use of the antibody or fragment in treatment or prophylaxis, in particular the treatment or prophylaxis of VEEV infection.
